Download Image
    
Share
  
Post
$0 $1,000 $2,000+ -25+% 0% 25% 50% Treatment cost (US$) Efficacy vs. cost for COVID-19 treatments +56 more high-profit drugs PPIs -46% BMS mAbs -36% >$2,000 Darunavir -34% Acetaminophen -28% Cenicriviroc -28% >$2,000 Lufotrelvir >$2,000 Dexamethasone Losartan Sargramostim >$2,000 Cannabidiol Lopinavir/ritonavir Ravulizumab >$2,000 Remdesivir $3,120 Conv. Plasma $5,000 Sarilumab >$2,000 Ibuprofen Masks Molnupiravir mutagenic/teratogenic Aspirin Tocilizumab Favipiravir Paxlovid Ratutrelvir Famotidine Vitamin C Sotrovimab $2,100 Colchicine TMPRSS2 i.. NAC Amubarvimab/r.. Vilobelimab $6,350 Ensitrelvir Azvudine Budesonide Probiotics HCQ Zinc Antiandro.. Sleep Metformin Vitamin A Melatonin Tixagevimab/c.. Bebtelovimab Nitric Oxide Quercetin H1RAs CPC Vitamin D H. Peroxide Exercise Sunlight Fluvox. Curcumin N. Sativa NaHCO₃ Casirivimab/i.. $2,100 Bamlanivimab/e.. Ensovibep >$2,000 PVP-I pH+ Diet Regdanvimab $2,100 Thermotherapy Ivermectin Lifestyle / free No prescription Prescription required High-cost Lowerrisk Higherrisk c19early.org April 2026 USA official early treatments COVID-19 involves the interplay of 500+ host/viral proteins/factors, modulated by many treatments. 0.5% of 11,000+proposed treatments show efficacy with ≥3 studies.Protocols combine treatments, none are 100% effective.c19early analyzes over 6,500 studies for 218 treatments.
Bofutrelvir (FB2001) is an intravenously administered small molecule covalent inhibitor of the SARS-CoV-2 main protease (Mpro/3CLpro). Recent:
Hu
Chen.
Apr 27
 Chen et al., Journal of Virology, doi:10.1128/jvi.02223-25 SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir
In vitro and mouse study showing differential resistance of SARS-CoV-2 3CLpro T21I/E166A mutations to simnotrelvir, bofutrelvir, nirmatrelvir, and ensitrelvir. The resistant isolate SARS2-T21I/E166A showed 4.3-9.2-fold resistance to simno..
Aug 8
2022
 Hu et al., International Conference on Emerging Infectious Diseases, August 2022 Safety, Pharmacokinetics, and Predicted Lung Concentration of a Novel SARS-CoV2 Mpro Inhibitor in Healthy Volunteers
Phase 1 RCT 120 healthy volunteers (80 US, 40 China) showing safety and tolerability of FB2001 (bofutrelvir).